FSD Pharma Inc , through its subsidiaries, operates as a pharmaceutical research and development company.
FSD Pharma is a micro cap stock with a total market cap of 52.76M.
They trade on the NASDAQ and had their IPO 5 years
FSD Pharma currently employs 17 people.
News Relating to $HUGE
Business Wire
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
Monday May 08 2023 at 08:50
TORONTO–(BUSINESS WIRE)—- $HUGE #FSDPharma–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings wit.
Proactive Investors
FSD Pharma receives regulatory clearance for proposed Phase 1 clinical trial of multiple sclerosis drug candidate Lucid-MS
Tuesday Feb 07 2023 at 10:14
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) told investors it has received a No Objection Letter (NOL) from Health Canada for its proposed Phase 1 clinical trial of LUCID-21-302 (Lucid-MS), a novel drug candidate for the treatment of multiple sclerosis (MS), providing it with regulatory approval to move forward with the trial in Canada. The Toronto-based biopharmaceutical company said the first-in-human clinical trial will evaluate the safety and tolerability of Lucid-MS, a neuroprotective compound with a unique mechanism of action for the treatment of MS.
Proactive Investors
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS
Monday Jan 30 2023 at 09:09
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) at two clinical sites in the US while a Canadian site is to be ready to recruit soon. The Toronto-based biopharmaceutical company said FSD201 is a proprietary anti-inflammatory compound with the potential to address a wide range of inflammatory diseases and associated conditions.
Proactive Investors
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS
Tuesday Jan 17 2023 at 10:12
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis (MS). In a statement, FSD Pharma called Lucid-MS a “first-in-class neuroprotective compound” with a novel mechanism action that has shown to prevent myelin degradation, which can cause MS and other neurodegenerative diseases.
Proactive Investors
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
Friday Jan 13 2023 at 09:46
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months. “FSD Pharma is focused on the advancement of its drug candidates toward the clinic, and we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans,” the company’s interim CEO Anthony Durkacz said in a statement.
Proactive Investors
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
Monday Jan 09 2023 at 10:18
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The Toronto-based biopharma firm told investors it has also appointed a number of new doctors to its Scientific and Clinical Expert Committee and is investigating other products addressing acute medical needs due to substances of abuse such as alcohol.
Proactive Investors
FSD Pharma announces changes to its board of directors
Tuesday Nov 29 2022 at 07:18
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.
Proactive Investors
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder
Tuesday Sep 06 2022 at 10:48
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and notice of authorization from Health Canada for its Phase 2 clinical trial of FSD201. The Toronto-based biopharma firm said the corresponding study protocol is titled “A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome.
Proactive Investors
FSD Pharma says Lucid Psycheceuticals subsidiary files patent for novel PEA formulations; presents preclinical toxicology results at international symposium
Wednesday Jul 13 2022 at 10:23
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The Toronto-based biotechnology company said the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma (CSE:HUGE, NASDAQ:HUGE).
Proactive Investors
FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder
Tuesday May 31 2022 at 10:26
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration (FDA) and Health Canada for its planned Phase 2 clinical trial of FSD-201 for the treatment of a yet-to-be-disclosed inflammatory disorder. The biotech noted that FSD-201, its proprietary formulation of ultra micronized palmitoylethanolamide, or ultramicronized PEA, was shown to be safe and well tolerated during a Phase 1 clinical trial.
Insider Trading
(Original Source: SEC.GOV)
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Over the last 3 months, there has been no insider trading.
Debt & Income Analysis
(Original Source: SEC.GOV)
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
$HUGE’s Income Quality of 0.98 is greater than its Industry Group of 0.8 (22.5% greater)
$HUGE’s Income Quality of 0.98 is greater than its Major Industry Group of 0.81 (21.0% greater)
$HUGE’s Income Quality of 0.98 is greater than its Sector of 0.83 (18.1% greater)
(Original Source: SEC.GOV)
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
$HUGE’s Current Ratio of 2.28 is lower than its Industry Group of 4.51 (-49.4% lower)
$HUGE’s Current Ratio of 2.28 is lower than its Major Industry Group of 4.13 (-44.8% lower)
$HUGE’s Current Ratio of 2.28 is in line with its Sector of 2.48 (-8.1% lower)
Value Analysis
(Original Source: SEC.GOV)
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Cannot compare a negative PE Ratio (-1.86 & -1.4)
Cannot compare a negative PE Ratio (-1.86 & -1.22)
Cannot compare a negative PE Ratio (-1.86 & -0.12)
(Original Source: SEC.GOV)
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
$HUGE’s PB Ratio of 1.62 is greater than its Industry Group of 1.39 (16.5% greater)
$HUGE’s PB Ratio of 1.62 is greater than its Major Industry Group of 1.47 (10.2% greater)
$HUGE’s PB Ratio of 1.62 is in line with its Sector of 1.7 (-4.7% lower)
Efficiency Analysis
(Original Source: SEC.GOV)
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
$HUGE’s ROE of -0.87 is lower than its Industry Group of -0.47 (-85.1% lower)
$HUGE’s ROE of -0.87 is lower than its Major Industry Group of -0.41 (-112.2% lower)
Cannot compute a percentage difference when there are zeros in the calculation
(Original Source: SEC.GOV)
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
$HUGE’s ROCE of -0.97 is lower than its Industry Group of -0.43 (-125.6% lower)
$HUGE’s ROCE of -0.97 is lower than its Major Industry Group of -0.38 (-155.3% lower)
$HUGE’s ROCE of -0.97 is lower than its Sector of 0.01 (-9800.0% lower)